A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy

The purpose of this study is to determine the safety and feasibility of administering the Tetanus Diptheria Vaccine (Td) or Polio Boost Immunization (IPOL) to patients with metastatic melanoma who are receiving immune checkpoint inhibitor (IO) therapy per standard of care. Subjects will have the vaccine at cycle 4 of IO therapy and will have research blood and tissue samples collected prior to starting IO therapy, at cycle 4 prior to vaccine administration, and at 12-17 days post vaccine.

Trial Details

NCT ID
NCT05077137
Phase
PHASE1
Sponsor
Duke University
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Tetanus Diptheria Vaccine
  • Polio Boost Immunization
Locations (sample)
  • Durham, North Carolina, United States|35.99403,-78.89862

Key Eligibility Criteria

  • Histologically confirmed advanced metastatic melanoma
  • Male or female participants who are at least 18 years of age on the day of signing informed consent
  • Participants must be planned or scheduled by their treating physician to receive PD-1 therapy or PD-1 plus anti CTLA-4 therapy as standard of care
  • Participant (or legally acceptable representative if applicable) provides written informed consent for the trial

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →